Founded in 2008 by medical device veterans, Minerva leverages deep industry expertise to create innovative gynecological solutions for use in hospitals, ambulatory surgical centers, and physician offices. The company differentiates through its broad product portfolio addressing multiple anatomies and treatment settings, though it remains in early commercial stage with revenue challenges limiting its competitive positioning.
Cyborg Score Rationale
Despite addressing a substantial market opportunity in women's health, Minerva faces significant headwinds including minimal TTM revenue (~$12M), persistent operating losses (-$6.1M), and a reverse stock split history indicating compliance struggles. The company's commercial-stage status and limited financial resources constrain near-term growth prospects.
Top Insights
Addresses abnormal uterine bleeding affecting ~20% of women, representing a substantial untreated market opportunity
Product portfolio includes multiple FDA-cleared minimally invasive devices (Symphion, Minerva ES, Resectr) enabling alternatives to hysterectomy
Commercial-stage company with TTM revenue of ~$12M and operating losses of -$6.1M indicates early monetization challenges
Underwent 20-for-1 reverse stock split in October 2023 to maintain NASDAQ compliance, signaling stock price pressure
Named Competitors
Endometrial ablation devices — Established larger medical device companies with gynecological portfolios
Hysterectomy alternatives — Traditional surgical and minimally invasive competitors